A New Tool for CRISPR-Cas13a-BasedCancer Gene Therapy

Código QR

A New Tool for CRISPR-Cas13a-BasedCancer Gene Therapy

Guardado en:

Detalles Bibliográficos
Autores principales:	Jinliang Gao, Tao Luo, Na Lin, Shuyan Zhang, Jinke Wang
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8a97ede4c457422e94c3f2af9abab9c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
por: Yonggang Lu, et al.
Publicado: (2021)

lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC
por: Bohao Zheng, et al.
Publicado: (2021)

p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells
por: Anna C Cunningham-Edmondson, et al.
Publicado: (2009)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Xiaoyan Zhang, et al.
Publicado: (2021)

Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial
por: Holly Keane, et al.
Publicado: (2021)

Differentiation therapy for myeloid malignancies: beyond cytotoxicity
por: Ryan J. Stubbins, et al.
Publicado: (2021)

Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology
por: Fanny S. Krebs, et al.
Publicado: (2021)

EBV based cancer prevention and therapy in nasopharyngeal carcinoma
por: Ya Cao
Publicado: (2017)

Microbiome dysbiosis in lung cancer: from composition to therapy
por: Ning-Ning Liu, et al.
Publicado: (2020)

A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction
por: Kalyan Nadiminti, et al.
Publicado: (2021)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Dana S. Neel, et al.
Publicado: (2017)

Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling
por: Feng Liu, et al.
Publicado: (2017)

Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Jessica S. Donington, MD
Publicado: (2021)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Jin Yuan MD, et al.
Publicado: (2021)

Decreased risk of breast cancer associated with oral bisphosphonate therapy
por: Mathew A, et al.
Publicado: (2012)

Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy
por: Yu BF, et al.
Publicado: (2015)

MET targeted therapy for lung cancer: clinical development and future directions
por: Feng Y, et al.
Publicado: (2012)

Traditional Chinese Medicine Therapy for Esophageal Cancer: A Literature Review
por: Luchang Cao MB, et al.
Publicado: (2021)

Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
por: Matthew A. Wall, et al.
Publicado: (2021)

Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
por: Chan VTC, et al.
Publicado: (2011)

Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
por: Razan Alzeibak, et al.
Publicado: (2021)

Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy
por: Yael Artzy-Randrup, et al.
Publicado: (2021)

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
por: Douglas Yee, et al.
Publicado: (2021)

Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Publicado: (2021)

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
por: Steven P. Angus, et al.
Publicado: (2021)

Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: V. La, et al.
Publicado: (2017)

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity
por: Simon Timbrell, et al.
Publicado: (2021)

The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
por: Zhang Zhiyu, et al.
Publicado: (2021)

Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Publicado: (2021)

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
por: Frank P. Lin, et al.
Publicado: (2021)

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Mary Kathryn Abel, et al.
Publicado: (2021)

Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases
por: Omar Alhalabi, et al.
Publicado: (2021)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
por: Stephen Johnston, et al.
Publicado: (2021)

Radiation recall dermatitis following letrozole administration in patient with a remote history of radiation therapy
por: Evan Sweren, et al.
Publicado: (2021)

Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
por: Aphinives P, et al.
Publicado: (2014)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Costanza Paoletti, et al.
Publicado: (2021)

Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
por: Saeed S. Akhand, et al.
Publicado: (2021)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Corey Smith, et al.
Publicado: (2021)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: V. La, et al.
Publicado: (2021)